Management of Childhood Asthma

Authored by , Reviewed by Prof Cathy Jackson | Last edited | Meets Patient’s editorial guidelines

This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Asthma article more useful, or one of our other health articles.

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

See also the separate Diagnosing Childhood Asthma in Primary Care article.

Asthma is the most common respiratory disorder of children. Chronic inflammation of the bronchial mucosa and hyper-reactive airways results in bronchoconstriction and reversible airway narrowing. It typically presents with wheeze, dry cough, difficulty breathing and/or chest tightness.

Clinical Editor's comments (October 2017)
Dr Hayley Willacy recently read a cautionary abstract looking at antibiotic prescriptions for children with asthma.[Baan E, et al. Antibiotic use in children with asthma. Abstract no: OA3449. European Respiratory Society International Congress. Milan, Italy. 2017.] The study included 1.5 million children from the UK, including around 150,000 with asthma, and a further 375,000 from the Netherlands, of whom around 30,000 had asthma. They compared antibiotic prescriptions for children with and without asthma and compared the situation in the Netherlands with that in the UK. The researchers found that children with asthma were approximately 1.6-times more likely to be prescribed antibiotics, compared with children who did not have asthma. They also found that antibiotic prescription rates were almost twice that in the UK overall. These results may show that asthma symptoms are being mistaken for respiratory tract infections, or that antibiotics are being given as prevention, even though guidelines do not support this.

Managing childhood asthma involves both an appreciation of current treatment practice and also a willingness to educate and support the child and their family in the longer term. Different phenotypes of childhood asthma are increasingly being recognised[1]:

  • Transient early wheezers where wheezing is commonly associated with viral upper respiratory infections. This is most likely to be grown out of by about the age of 3 years, particularly in those children without a family or personal history of atopy.
  • Non-atopic wheezers who again are likely to outgrow symptoms by early school age.
  • Children who go on to develop a more persistent, atopic asthma, associated with raised immunoglobulin E (IgE) levels.

Acute asthma is a relatively common paediatric emergency. Treat acute asthma as severe until proven otherwise and refer children who respond inadequately to community treatment urgently to hospital. Severe asthma in children is the third most common cause of hospital admission and the most common cause of paediatric intensive care unit (ICU) admission[2, 3].


It is vital to recognise the severity of an acute asthma attack. Clinical signs are a poor indicator of the degree of airways obstruction and some with acute severe asthma may not appear distressed.

Always assess and record:

  • Pulse rate.
  • Respiratory rate.
  • Oxygen saturations (SpO2).
  • Degree of breathlessness (eg, ability to complete sentences, and to feed).
  • Use of accessory muscles of respiration (feel the neck muscles for involvement in breathing).
  • Amount of wheezing (with increasing severity, wheeze may become biphasic or less apparent).
  • Degree of agitation and conscious level.
Clinical assessment of the severity of an acute asthma attack in those aged over 2 years[4]
Acute severe
  • Oxygen saturations (SpO2) <92%.
  • Too breathless to talk.
  • Pulse >125 in those aged over 5 years or >140 in 2-5 year-olds.
  • Respiratory rate >30 in those aged over 5 and >40 in 2- to 5-year-olds.
  • Use of accessory neck muscles.
  • Peak expiratory flow rate (PEFR) 33-50% best/predicted (age over 5 years).
SpO2 <92% plus any of:
  • Silent chest.
  • Cyanosis.
  • Poor respiratory effort.
  • Agitation.
  • Confusion.
  • Coma.
  • PEFR 33-50% best/predicted (age over 5 years).
Clinical assessment of the severity of an acute asthma attack in those aged under 2 years[4]
  • SpO2 ≥92%.
  • Audible wheezing.
  • Using accessory muscles.
  • Still feeding.
  • SpO2 <92%.
  • Cyanosis.
  • Marked respiratory distress.
  • Too breathless to feed.
Most infants are audibly wheezy with intercostal recession but not distressed. Life-threatening features include apnoea, bradycardia and poor respiratory effort.

Children should be monitored carefully and assessed repeatedly to determine the need for admission to secondary care or for transfer to a high-dependency unit (HDU) or paediatric intensive care unit (PICU), where there are features of poorly responsive severe asthma or life-threatening asthma.


These include[4]:

  • Peak expiratory flow rate (PEFR) in children aged over 5 years (use best of three readings, expressed as a % of personal best PEFR).
  • Oxygen saturation - should be available in primary care, as low oxygen saturations (<92%) after initial bronchodilator therapy indicate a more severe subgroup of patients, in whom inpatient treatment may be required.
  • CXRs and arterial blood gases are not routinely indicated, as their information yield is rarely high.


Children with severe or life-threatening asthma should be transferred to hospital urgently.

The threshold for admission should otherwise be lower for:

  • Asthma attack in late afternoon or at night.
  • Recent hospital admission or previous severe attack.
  • Concern over social circumstances or ability to cope at home.

Children aged 2 years and over

  • Moderate asthma:
    • Beta2 agonist 2-10 puffs via spacer and (face mask for age 2-5 years; mouthpiece if over 5 years); give one puff of beta2 agonist every 30-60 seconds up to 10 puffs according to response. Consider oral prednisolone (20 mg for age 2-5 years; 30-40 mg for age over 5 years).
    • If there is a poor response: arrange hospital admission.
    • If there is a good response: continue beta2 agonist via spacer or nebuliser, as needed but not exceeding four hourly. If symptoms are not controlled, repeat beta2 agonist and refer to hospital. Continue prednisolone for up to three days. Arrange review within 48 hours. Consider referral to a secondary care asthma clinic if there is a second attack within 12 months.
  • Acute severe asthma:
    • Oxygen via face mask; 10 puffs of beta2 agonist or nebulised salbutamol (2.5 mg for age 2-5 years; 5 mg for age over 5 years), oral prednisolone (20 mg for age 2-5 years; 30-40 mg for age over 5 years).
    • Assess response to treatment 15 mins after beta2 agonist:
      • If there is a good response: continue beta2 agonist via spacer or nebuliser, as needed but not exceeding four hourly. If symptoms are not controlled, repeat beta2 agonist and refer to hospital. Continue prednisolone for up to three days. Arrange review within 48 hours. Consider referral to a secondary care asthma clinic if there is a second attack within 12 months.
      • If there is a poor response: repeat beta2 agonist and arrange hospital admission.
  • Acute life-threatening asthma:
    • Oxygen via face mask, nebulise with salbutamol (2.5 mg for age 2-5 years; 5 mg for age over 5 years) and ipratropium 0.25 mg; oral prednisolone (20 mg for age 2-5 years; 30-40 mg for age over 5 years) - or intravenous hydrocortisone (50 mg for age 2-5 years; 100 mg for age over 5 years) if vomiting. Stay with the child while awaiting ambulance for immediate transfer to hospital.

Current evidence does not support increasing the dose of inhaled corticosteroids (ICS) as part of a self-initiated action plan to treat exacerbations in adults and children with mild-to-moderate asthma. Increased ICS dose is not associated with a statistically significant reduction in the odds of requiring rescue oral corticosteroids for the exacerbation, or of having adverse events, compared with a stable ICS dose[5].

For children aged 2 years and over, give oral steroids early in the treatment of acute asthma attacks. For children aged less than 2 years, consider steroid tablets early in the management of severe asthma attacks in the hospital setting. However, systemic corticosteroids do not affect the long-term prognosis in children with their first viral-induced wheezing episode and should be used cautiously during acute episodes[6].

Much of the management of asthma has been delegated to asthma nurses - either within the practice or within the community.

It is very important to consider the upper respiratory tract when treating asthma. It is much more difficult to treat asthma successfully if co-existing allergic rhinitis (perennial or seasonal) is not adequately controlled[7].


Editor's note

Dr Sarah Jarvis, 2nd April 2021
Reference to National Institute for Health and Care Excellence (NICE) guidance on air quality at home[8]has been added to an update to the NICE guidance on asthma[9]

Updated recommendations include:

  • Inclusion of approaches to minimising indoor air pollution and reducing exposure to outdoor air pollution personalised action plans. 
  • Advice to patients on the role of indoor air pollutants - including nitrogen dioxide, damp, mould, particulate matter and volatile organic compounds (VOCs) - in triggering or exacerbating asthma.
  • Consideration of housing as a possible cause of cough or wheeze and, if relevant, assistance to patients/parents in requesting a housing assessment from the local authority.
  • Patients whose asthma is triggered by household sprays, air fresheners or aerosols should be advised to avoid them and use non-spray alternatives.
  • Allergen avoidance - commonly recommended in patients with asthma but there is a lack of good evidence showing its efficacy[10]:
    • House dust mite - a Cochrane review concluded that chemical and physical methods of house dust mite avoidance could not currently be recommended[11]. However, some families are very committed to trigger avoidance and suggestions can include:
      • Complete bed-covering barrier systems.
      • Removing all carpets.
      • Removing soft toys from the bed.
      • High-temperature washing of bed linen.
      • Acaricides to soft furnishings.
      • Improving ventilation with or without dehumidification.
    • Pet allergy - there are no controlled trials looking at removing domestic pets. There is varied anecdotal evidence with some experiencing no benefit on removing the pet and others, with continuing exposure to the pet, developing some tolerance. However, it seems sensible not to have a cat or dog if someone in the family already has asthma.
  • Dietary manipulation - studies looking at supplementation with vitamin C, vitamin E, magnesium and fish oil have not shown significantly beneficial effects[10].
  • Complementary and alternative therapies:
    • There is insufficient evidence to recommend acupuncture, herbal or Chinese medicines, homeopathy, hypnosis or relaxation therapies.
    • Air ionisers offer no benefit to the treatment of asthma.
  • Smoking cessation advice to caregivers and teenagers with asthma. Direct or passive smoking reduces lung function and increases the need for rescue medication and long-term 'preventer' treatment.
  • Physical exercise therapy - may increase overall fitness but is of no specific benefit to asthma.
  • Family therapy - where asthma is difficult to control, this may be a useful adjunct.
  • Patient/carer education with the aim of creating partnership with family and child and confident self-care.
  • Written asthma action plans for self-management lead to consistently improved outcomes[12].
  • Consider care links - eg, to school and transition to adult services. Schools should have their own asthma policy; staff are not required to administer asthma drugs except in an emergency but most are supportive of children with asthma and receptive to training in managing asthma and the correct way to administer inhaled drugs.
  • Links to local and national patient groups for support and information.


As for adult management of chronic asthma, current national guidelines advocate a stepwise approach. Start at the step most appropriate to the initial severity of symptoms. Aim to achieve early control and then decrease treatment by stepping down to the lowest controlling step once stable. Always check concordance and reconsider diagnosis if response to treatment is poorer than anticipated.

Management of chronic asthma in children aged under 5

Step 1: mild intermittent asthma - inhaled short-acting beta2 agonists as needed.
Step 2: regular preventer therapy - add inhaled steroid 200-400 micrograms/day (beclometasone diproprionate or equivalent) or a leukotriene antagonist if inhaled steroid cannot be used. Start at the dose of inhaled steroid appropriate to the severity of the disease.
Step 3: add-on therapy - for children aged over 2 years, consider the addition of a leukotriene antagonist or inhaled steroid 200-400 micrograms/day (dependent on what drug they received already as Step 2). For children under 2 years, consider proceeding to Step 4.
Step 4: persistent poor control - refer to a respiratory paediatrician.
Management of chronic asthma in children aged 5-12 years

Step 1: mild intermittent asthma - inhaled short-acting beta2 agonists as needed.
Step 2: regular preventer therapy - add inhaled steroid 200-400 micrograms/day (beclometasone diproprionate or equivalent). 200 micrograms is an appropriate starting dose for most patients but judge according to the severity of disease.
Step 3: add-on therapies - add in a long-acting inhaled beta2 agonist (LABA) but if response is poor, stop. If the asthma is still not controlled, increase the dose of inhaled corticosteroid to 400 micrograms/day (beclometasone diproprionate or equivalent) and then add either a leukotriene receptor antagonist or slow-release theophylline.
Step 4: persistent poor control - increase inhaled steroid to 800 micrograms/day (beclometasone diproprionate or equivalent).
Step 5: continuous or frequent use of oral steroids - use in the lowest dose to provide control whilst maintaining high-dose inhaled steroids and refer to respiratory paediatricians.

Management of those aged over 12 years is as for adults. See the separate Management of Adult Asthma article.

Beta2 agonists

  • Short-acting beta2 agonists work quickly and provide symptomatic relief. No benefits have been shown from regular dosing. Good asthma control is associated with little or no need for short-acting beta2 agonists. Using two or more canisters of beta2 agonists per month or >10-12 puffs per day, is a marker of poorly controlled asthma that puts individuals at risk of fatal or near-fatal asthma. Thus, patients overusing inhaled short-acting beta2 agonists should have their asthma management reviewed.
  • LABAs are useful in symptomatic control, particularly in the treatment of nocturnal asthma; however, they should not be used as relief for an acute attack. Any child using a LABA should also be using regular inhaled corticosteroid, as failure to do this increases the risk of life-threatening attacks. LABAs are the first-choice add-on therapy where control on normal-dose inhaled steroids remains sub-optimum in children aged over 5 years.
  • Oral preparations of beta2 agonists have been used extensively in the past with children but are less effective than inhaled preparations and have more side-effects.

Inhaled corticosteroids (ICS)

  • Regular inhaled corticosteroids are recommended where[13]:
    • Beta2 agonists are being used more than two times per week.
    • Symptoms disturb sleep at least once a week.
    • A child has had an exacerbation in the previous two years, requiring systemic corticosteroids.
  • They should be taken regularly and concordance may be an issue. Improvement in symptoms usually takes 3-7 days.
  • No impact on later development of asthma has been shown by early intervention with regular inhaled steroids in episodically wheezy children aged under 5 years[14].
  • Systemic absorption[13]:
    • High doses of ICS used for prolonged periods can induce adrenal suppression. ICS have occasionally been associated with adrenal crisis and coma in children.
    • Excessive doses should therefore be avoided and the dose of an ICS should be no higher than necessary to keep a child's asthma under good control.
    • Growth restriction associated with systemic corticosteroid therapy does not seem to occur with recommended doses of ICS; although initial growth velocity may be reduced, there appears to be no effect on achieving normal adult height.
  • Candidiasis of the throat and mouth may occur, particularly with higher doses of ICS. Strategies to reduce the risk include use of a spacer and rinsing the mouth with water or cleaning the teeth following inhalation.

Leukotriene receptor antagonists

  • These are an option as 'add-on' therapy to poorly controlled asthma. In children aged over 5 years, a LABA and ICS to a dose of 400 micrograms beclometasone diproprionate or equivalent should be trialled before their use.
  • Leukotriene receptor antagonists improve lung function, decrease exacerbations and improve symptoms in some patients but there appears to be wide individual difference in response.
  • They should not be considered 'steroid-sparing'.


  • These are another option as 'add-on' therapy for children aged over 5 years.
  • There is little evidence demonstrating the increased benefit of one particular 'add-on' approach (further increase dose of ICS 800 micrograms beclometasone diproprionate, leukotriene receptor antagonist, oral theophylline or slow-release oral beta2 agonist) to guide choice.
  • Theophyllines and oral beta2 agonists are associated with higher risk of side-effects.
  • With any add-on therapy, have a trial for a predetermined time period and stop the therapy if, on assessment, it has no benefit.

NICE recommends omalizumab as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in children aged 6 years and older who need continuous or frequent treatment with oral corticosteroids (defined as four or more courses in the previous year). Omalizumab should only be initiated by a specialist.

Optimised standard therapy is defined as a full trial of and, if tolerated, documented compliance with high-dose ICS, LABAs, leukotriene receptor antagonists, theophyllines and oral corticosteroids.

Indications for specialist referral in children include:

  • The diagnosis is unclear or in doubt (the younger the child, the more difficult it is to be sure that wheezing is due to asthma):
    • Unexpected clinical findings (for example, abnormal voice, focal chest signs, dysphagia, inspiratory wheeze, stridor).
    • Symptoms present from birth, or a perinatal lung problem.
    • Excessive vomiting or possetting.
    • Severe upper respiratory tract infection.
    • Persistent productive cough.
  • Family history of unusual chest disease.
  • Failure to thrive.
  • Parental anxiety.
  • Inadequate response to maximum guideline treatment, particularly if oral corticosteroids are needed frequently, or use of the maximum dose of ICS.

Influenza vaccine - children with asthma who require continuous or repeated use of inhaled/systemic steroids or with previous exacerbations requiring hospital admission should be immunised[17]. If children receive repeated systemic steroids sufficient to cause immunosuppression they also require pneumococcal vaccination.

See the separate Which Device in Asthma? and Nebulisers in General Practice articles.

  • A metered dose inhaler (MDI) plus spacer device is the first-line choice for the delivery of ICS therapy in those aged over 5 years.
  • Where poor compliance with MDI and spacer is likely to jeopardise good asthma control, alternative devices should be considered whilst still looking to minimise systemic absorption.
  • For those aged less than 5 years, corticosteroid and bronchodilator therapy should be delivered via MDI/spacer and face mask combination. Nebulisers may be considered where MDIs and spacers are not effective or if the child's clinical condition is poor.
  • Children and their carers need to be trained in the use of their chosen device prior to prescribing and should be suitability reviewed looking at compliance and technique.
  • Reduced quality of life.
  • Reduced growth, usually as a result of poor control rather than treatment.
  • Psychological morbidity - although differences appear to be the result of poor health rather than asthma itself[20].
  • Absence from school and educational disadvantage.
  • In one study of children admitted to the PICU, there was a 22% complication rate (eg, aspiration pneumonia, ventilator-associated pneumonia, pneumomediastinum, pneumothorax and rhabdomyolysis), increased by intubation[3].

Further reading and references

  1. Russell G; Wheeze in preschool children. BMJ. 2008 Jun 16.

  2. Mannix R, Bachur R; Status asthmaticus in children. Curr Opin Pediatr. 2007 Jun19(3):281-7.

  3. Carroll CL, Zucker AR; The increased cost of complications in children with status asthmaticus. Pediatr Pulmonol. 2007 Oct42(10):914-9.

  4. British Guideline on the management of asthma; Scottish Intercollegiate Guidelines Network - SIGN (2016)

  5. Kew KM, Quinn M, Quon BS, et al; Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. 2016 Jun 7(6):CD007524. doi: 10.1002/14651858.CD007524.pub4.

  6. de Benedictis FM, Attanasi M; Asthma in childhood. Eur Respir Rev. 2016 Mar25(139):41-7. doi: 10.1183/16000617.0082-2015.

  7. Brozek JL, Bousquet J, Baena-Cagnani CE, et al; Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010 Sep126(3):466-76. doi: 10.1016/j.jaci.2010.06.047.

  8. Indoor air quality at home. NICE guideline [NG149], January 2020

  9. Asthma: diagnosis, monitoring and chronic asthma management; NICE Guideline (November 2017 - last updated April 2021)

  10. Currie GP, Devereux GS, Lee DK, et al; Recent developments in asthma management. BMJ. 2005 Mar 12330(7491):585-9.

  11. Gotzsche PC, Johansen HK; House dust mite control measures for asthma. Cochrane Database Syst Rev. 2008 Apr 16(2):CD001187.

  12. Thoonen BP, Schermer TR, Van Den Boom G, et al; Self-management of asthma in general practice, asthma control and quality of life: a randomised controlled trial. Thorax. 2003 Jan58(1):30-6.

  13. British National Formulary (BNF); NICE Evidence Services (UK access only)

  14. Townshend J, Hails S, McKean M; Management of asthma in children. BMJ. 2007 Aug 4335(7613):253-7.

  15. Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201); NICE Technology appraisal guidance, April 2013

  16. Asthma; NICE CKS, Dec 2013 (UK access only)

  17. Immunisation against infectious disease - the Green Book (latest edition); Public Health England

  18. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over; NICE Technology Appraisal Guidance, March 2008

  19. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years; NICE Technology Appraisal Guidance, November 2007

  20. Calam R, Gregg L, Goodman R; Psychological adjustment and asthma in children and adolescents: the UK Nationwide Mental Health Survey. Psychosom Med. 2005 Jan-Feb67(1):105-10.